Professional Documents
Culture Documents
REVIEW LITERATURE
JOURNAL
TOPIC:- NEONATAL JAUNDICE AND PHOTOTHERAPY
SUBMITED TO
PROFESSOR, PRINCIPAL,
INE MUNBAI
SUBMITED BY
INE MUMBAI
Objectives of journal presentation:
Research.
• Name of author:
Hakam Yaseen MD, CES, DUN (France), FRCPCH (UK),
Mona Khalaf MRCP, Najat Rashid PhD and Maha Darwich MD, CES
• Title:
does prophylactic phototherapy prevent hyperbilirubinemia in neonates with
abo incompatibility and positive coombs' test?
• Journal name:
Journal of Perinatology (2005) 25, 590–594. doi:10.1038/sj.jp.7211356;
published online 21 July 2005
• OBJECTIVE:
The objective of the study was to determine whether initiation of early
phototherapy in positive direct Coombs' test (DCT) with ABO-incompatible
newborns would prevent severe jaundice.
• STUDY DESIGN:
A prospective controlled study was performed at Al Qassimi Hospital.
Infants born at term and weighing >2000 g with ABO incompatibility and a
positive DCT were included in the study. Within their first 4 hours of life
and after parental consent, infants were enrolled into one of two groups:
prophylactic phototherapy group, which received phototherapy during the
first 24 hours of life (group I), or no prophylactic phototherapy, which
represents the control group (group II). Selection of infants to either group
was by 2-week alternative strategy.
Blood group, complete blood count (CBC), reticulocyte count, blood
smears, total serum bilirubin (TSB) and DCT were performed on cord blood
of all neonates born to mothers with O-positive blood group. CBC,
reticulocytes and TSB level were obtained in all enrolled infants at 12, 24,
48, 72, and 96 hours of life.
• RESULTS:
During the study period, 242 newborns with positive DCT were enrolled. A
total of 102 infants were allocated to the prophylactic phototherapy arm and
140 as controls. Prophylactic phototherapy was associated with a significant
decrease in the TSB at 24 hours (p=0.002) and at 48 hours (p=0.003) but not
later on. The total number of patients who had hyperbilirubinemia at any
time during the first 96 hours was significantly less in the prophylactic group
(17 vs 45 — p=0.006). Prolonged hospital stay because of phototherapy was
more frequent in the control group (p=0.03).
• CONCLUSION:
Prophylactic phototherapy was associated with a significant reduction of
TSB in the first 48 hours of life but not later on. Clinical benefits of this
strategy could not be proven.
2. Journal-
Name of author:
Sarici SU, Alpay F, Dündaröz MR, Ozcan O, Gökçay EDepartment of
Pediatrics, Gülhane Military Medical Academy, Ankara, Turkey.
Title: The efficacy and wavelengths of fiberoptic phototherapy and
conventional daylight phototherapy
Journal name:- The Turkish Journal of Pediatrics [2001, 43(4):280-285]
Type: Clinical Trial, Journal Article, Randomized Controlled Trial
TITAL :-
effect of clofibrate in jaundiced term newborns
NAME OF JOURNAL :-
February 2005, Volume 72, Issue 2, pp 123-126 academic journal pediatric
AUTHER :-
A. Mohammadzadeh, A. Sh. Farhat, R. Iranpour
OBJECTIVE:
Clofibrate is a glucuronosyl transferase inducer that has been proposed to
increase the elimination of bilirubin in neonates with hyperbilirubinemia.
The aim of this study was to characterize the therapeutic effect of clofibrate
in neonates born at full term and present with non-hemolytic jaundice
METHODS:
A clinical controlled study was performed in two groups of healthy full term
neonates. Thirty neonates were treated with a single oral dose of clofibrate
(100 mg/kg) plus phototherapy (clofibrate-treated group) while another 30
neonates (control group) received only phototherapy.
RESULT:
The mean plasma total bilirubin levels of 12th, 24th and 48th hours were
significantly lower in the clofibrate-treated group as compared with the
control group (P<0.0001, P<0.0001 and P=0.004, respectively). Treatment
with clofibrate also resulted in a shorter duration of jaundice and a
decreased use of phototherapy (P<0.0001). No side effects were observed.
CONCLUSION:
Although other pharmacological agents such as metalloporphyrins and Sn-
mesoporphyrin also seem to be effective in decreasing bilirubin production,
these products are not available for routine use and cannot be used because
the safety of these drugs has to be confirmed prior to their widespread use.
Therefore, clofibrate is now the only available pharmacological treatment of
neonatal jaundice.